An Intravascular Bioartificial Pancreas (iBAP)

血管内生物人工胰腺 (iBAP)

基本信息

  • 批准号:
    8823183
  • 负责人:
  • 金额:
    $ 22.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-23 至 2017-09-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Approximately 3 million Americans and around 24 million people worldwide are affected by Type 1 Diabetes (T1D). Glucose monitoring followed by exogenous insulin injection, allogeneic whole organ pancreas transplantation, and allogeneic islet transplantation are the most common treatments for T1D. These treatments have achieved glycemic control for many patients but result in serious complications. A bioartificial pancreas is a promising treatment for T1D because it contains functional islets. Unfortunately previous attempts at BAP development have been severely limited by insufficient mass transfer within the islet chamber. The founders of Silicon Kidney have developed silicon nanopore membranes (SNM) to achieve high-efficiency blood ultrafiltration while selectively retaining specific solutes for the Bioartificial Kidney Project and this project's successes are directly transferrable to the iBAP. The ultra-high-hydraulic-permeable characteristic of the SNM will enable appropriate mass transport (especially oxygen, glucose, and insulin) within the islet chamber to achieve optimal islet performance, while the ultra-selective characteristic of the SNM enable unprecedented immunoisolation. The iBAP will be connected between an arterial and venous graft and a pressure drop across the Islet Chamber will produce an ultrafiltrate flow within the Islet Chamber. The ultrafiltrate will provide convective mass transport of nutrients (especially oxygen and glucose) to the Islet Chamber and insulin to the blood channels. The long-term objective of our project is to create the intravascular Bioartificial Pancreas (iBAP) to achieve exogenous insulin independent glycemic control of Type 1 Diabetes (T1D). This Phase I SBIR project will prove the feasibility of the iBAP by demonstrating proper Islet Chamber performance in vitro and iBAP hemocompatibility in vivo.
 描述(由申请人提供):大约300万美国人和全球约2400万人受1型糖尿病(T1D)影响。葡萄糖监测后进行外源性胰岛素注射、同种异体全器官胰腺移植和同种异体胰岛移植是T1D最常见的治疗方法。这些治疗对许多患者实现了血糖控制,但导致严重的并发症。一种生物人工胰腺, 这是一种很有前途的T1D治疗方法,因为它含有功能性胰岛。不幸的是,之前对BAP开发的尝试因胰岛室内质量转移不足而受到严重限制。硅肾的创始人开发了硅纳米孔膜(SNM),实现高效血液超滤,同时选择性保留特定溶质 生物人工肾项目,该项目的成功可直接转移到 iBAP。SNM的超高水力渗透特性将使得能够在胰岛室内进行适当的质量输送(特别是氧气、葡萄糖和胰岛素),以实现最佳的胰岛性能,而SNM的超选择性特性使得能够进行前所未有的免疫隔离。iBAP将连接在动脉和静脉移植物之间,胰岛室的压降将在胰岛室内产生超滤液流。超滤液将提供营养物质(特别是氧气和葡萄糖)到胰岛室和胰岛素到血液通道的对流质量运输。本项目的长期目标是建立血管内生物人工胰腺(iBAP),以实现1型糖尿病(T1D)的外源性胰岛素非依赖性血糖控制。该I期SBIR项目将通过证明体外适当的胰岛室性能和体内iBAP血液相容性来证明iBAP的可行性。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
An intravascular bioartificial pancreas device (iBAP) with silicon nanopore membranes (SNM) for islet encapsulation under convective mass transport.
血管内生物人工胰腺器件(IBAP),带有硅纳米孔膜(SNM),用于对流质量运输下的胰岛封装。
  • DOI:
    10.1039/c7lc00096k
  • 发表时间:
    2017-05-16
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Song S;Blaha C;Moses W;Park J;Wright N;Groszek J;Fissell W;Vartanian S;Posselt AM;Roy S
  • 通讯作者:
    Roy S
Correction: An intravascular bioartificial pancreas device (iBAP) with silicon nanopore membranes (SNM) for islet encapsulation under convective mass transport.
修正:血管内生物人工胰腺装置 (iBAP) 具有硅纳米孔膜 (SNM),用于在对流质量传输下封装胰岛。
  • DOI:
    10.1039/c7lc90058a
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Song,Shang;Blaha,Charles;Moses,Willieford;Park,Jaehyun;Wright,Nathan;Groszek,Joey;Fissell,William;Vartanian,Shant;Posselt,AndrewM;Roy,Shuvo
  • 通讯作者:
    Roy,Shuvo
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles Blaha其他文献

Charles Blaha的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles Blaha', 18)}}的其他基金

A high oxygen capacity cell scaffold for the intravascular bioartifical pancreas (iBAP)
用于血管内生物人工胰腺(iBAP)的高氧容量细胞支架
  • 批准号:
    9899079
  • 财政年份:
    2019
  • 资助金额:
    $ 22.44万
  • 项目类别:
A silicon nanopore membrane blood filter enabling anticoagulant free continuous renal replacement therapy for acute kidney injury
硅纳米孔膜血液过滤器可实现无抗凝剂的连续肾脏替代治疗急性肾损伤
  • 批准号:
    10546997
  • 财政年份:
    2019
  • 资助金额:
    $ 22.44万
  • 项目类别:
Development of advanced voltammetric method for basal neurotransmitter level measurement
开发用于基础神经递质水平测量的先进伏安法
  • 批准号:
    9796267
  • 财政年份:
    2019
  • 资助金额:
    $ 22.44万
  • 项目类别:
In Vivo Fluorescent Microscopy Analysis of Motor Cortex Activation by STN DBS
STN DBS 对运动皮层激活的体内荧光显微镜分析
  • 批准号:
    10023233
  • 财政年份:
    2018
  • 资助金额:
    $ 22.44万
  • 项目类别:
An implantable hemodialyzer for treatment of End-Stage Renal Disease
用于治疗终末期肾病的植入式血液透析器
  • 批准号:
    8714973
  • 财政年份:
    2014
  • 资助金额:
    $ 22.44万
  • 项目类别:
Cerebellar Modulation of Frontal Cortical Function
额叶皮质功能的小脑调节
  • 批准号:
    8418762
  • 财政年份:
    2009
  • 资助金额:
    $ 22.44万
  • 项目类别:
Cerebellar Modulation of Frontal Cortical Function
额叶皮质功能的小脑调节
  • 批准号:
    7656128
  • 财政年份:
    2009
  • 资助金额:
    $ 22.44万
  • 项目类别:
Cerebellar Modulation of Frontal Cortical Function
额叶皮质功能的小脑调节
  • 批准号:
    8033156
  • 财政年份:
    2009
  • 资助金额:
    $ 22.44万
  • 项目类别:
Cerebellar Modulation of Frontal Cortical Function
额叶皮质功能的小脑调节
  • 批准号:
    8239877
  • 财政年份:
    2009
  • 资助金额:
    $ 22.44万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 22.44万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了